TDSGF (Telo Genomics) OCF Yield %: -32.34 (As of Jun. 29, 2026)


What is Telo Genomics OCF Yield %?

Telo Genomics TDSGF +3.71% OCF Yield % is -32.34 as of Jun. 29, 2026. The stock has 2 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Telo Genomics ranks worse than 88.79% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Telo Genomics's Trailing 12-Month Cash Flow from Operations is $-0.95 Mil, and Market Cap is $2.83 Mil. Therefore, Telo Genomics's OCF Yield % for today is -32.34%.

The historical rank and industry rank for Telo Genomics's OCF Yield % or its related term are showing as below:

TDSGF' s OCF Yield % Range Over the Past 10 Years
Min: -32.34   Med: 0   Max: -32.34
Current: -32.34


During the past 13 years, the highest OCF Yield % of Telo Genomics was -32.34%. The lowest was -32.34%. And the median was %.

TDSGF's OCF Yield % is ranked worse than
88.79% of 214 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.03 vs TDSGF: -32.34

Telo Genomics's OCF Margin % for the quarter that ended in Mar. 2026 was %.


Telo Genomics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Telo Genomics OCF Yield % Related Terms


Telo Genomics OCF Yield % Historical Data

* Premium members only.

The historical data trend for Telo Genomics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telo Genomics OCF Yield % Chart

Telo Genomics Annual Data
Trend Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
OCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.18 -8.28 -14.02 -15.26 -24.87

Telo Genomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -45.80 -19.62 -19.48 -12.34 -26.52

TDSGF vs TMO, DHR, IDXX: OCF Yield % Comparison

For the Diagnostics & Research subindustry, Telo Genomics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telo Genomics OCF Yield % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Telo Genomics's OCF Yield % falls into.



Telo Genomics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Telo Genomics's OCF Yield % for the fiscal year that ended in Jun. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-1.704 / 6.8513015
=-24.87%

Telo Genomics's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-0.238 * 4 / 3.5893682
=-26.52%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -32.34 mean?
Telo Genomics (TDSGF) has a OCF Yield % of -32.34 as of Jun. 29, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Telo Genomics and its competitors. According to the industry distribution chart, Telo Genomics ranks #190 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 88.8%.
Is Telo Genomics' OCF Yield % too high?
Telo Genomics' current OCF Yield % is -32.34. Based on the distribution chart, Telo Genomics ranks #190 out of 214 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Telo Genomics' OCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Telo Genomics ranks #190 out of 214 companies for OCF Yield %. This places Telo Genomics in the lower half of its industry. The industry median OCF Yield % is 1.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Diagnostics & Research company?
The median OCF Yield % among Medical Diagnostics & Research companies is 1.03, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Telo Genomics and its competitors. For the Medical Diagnostics & Research industry, the median OCF Yield % is 1.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telo Genomics's current OCF Yield % is -32.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telo Genomics stock overvalued right now?
Telo Genomics (TDSGF) has a current OCF Yield % of -32.34. The current OCF Yield % is -32.34. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Telo Genomics (TDSGF), the current OCF Yield % is -32.34 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Telo Genomics Business Description

Other Exchanges 3D0A:GermanyTELO:Canada
Address 2255 York Avenue, Suite 203, Vancouver, BC, CAN, V6K 1C5
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.